Cannabis News Box

GW Pharmaceuticals turns over $108M in Q4 sales thanks to CBD-based medicine

Bethan Rose Jenkins, Cannabis News Writer/Editorial

January 27, 2020

Following the EU approval of a cannabis-derived epilepsy treatment called Epidiolex, British drugs company GW Pharmaceuticals is experiencing a major surge in sales. Headquartered in London, GW Pharma recently revealed its latest sales figures to investors; $108 million during the last quarter of 20...

CEO of GW Pharma talks about Epidiolex getting FDA approval

Bethan Rose Jenkins, Cannabis News Writer/Editorial

July 2, 2018

On Monday, Justin Gover hit a milestone in his career. He is the CEO of GW Pharmaceuticals – a company that created a cannabis-based medicine called Epidiolex. Not only is Epidiolex being used to treat two forms of epilepsy but also, it is non-psychoactive, what with it containing the cannabis com...

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Bethan Rose Jenkins, Cannabis News Writer/Editorial

May 3, 2018

A cannabis-based medication for epilepsy could be the first to gain approval by the Food and Drug Administration (FDA). Created by British company GW Pharmaceuticals, cannabis-based epilepsy treatment Epidiolex will undergo FDA review this June. Things are looking hopeful, with a panel of 13 advisors...

gw pharma